RxDoctor Payments Data

Michelle Starnes

Family · Hickory, NCNPI 1487052445

Payments from drug & device makers

$6,559in general payments, 2019–2025

Across 301 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • GSK$550
  • Lilly USA, LLC$442
  • Astellas Pharma US Inc$265
  • AstraZeneca$259
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$6,36297%
  • Education$1973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,559 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,071
Medicare patients
90
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$83,436
FarxigaDapagliflozin Propanediol39$33,022
JardianceEmpagliflozin25$31,736
EliquisApixaban37$26,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$22,465
JanuviaSitagliptin Phosphate12$19,661
MounjaroTirzepatide20$18,443
MyrbetriqMirabegron12$11,838
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen269$10,114
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,782
TrintellixVortioxetine Hydrobromide16$7,872
VyvanseLisdexamfetamine Dimesylate12$4,567
Dexlansoprazole DrDexlansoprazole11$3,822
SymbicortBudesonide/Formoterol Fumarate12$3,280
Omeprazole185$3,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,103$83,43667 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$259$45,08464 claims
Boehringer IngelheimJardiance$168$31,73625 claims
PfizerEliquis$197$26,50837 claims
GSKTrelegy Ellipta$550$22,46520 claims
MerckJanuvia$29$19,66112 claims
Lilly USA, LLCMounjaro$442$18,44320 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$146$12,43928 claims
Astellas Pharma US IncMyrbetriq$265$11,83812 claims
AbbVieSynthroid$1,498$1,99124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →